Synteract
CompanyUnited StatesFounded 2008
Synteract develops one asset, in phase 2 (Mitopure in chronic obstructive pulmonary disease). Mostly supplement acting on Mitochondrial biogenesis (PGC-1α) and autophagy; based in the United States, founded in 2008.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 3
- Signals
Pipeline
1Promotes mitophagy to remove damaged mitochondria and improve mitochondrial function.
Phase 2, Supplement, Mitochondrial biogenesis (PGC-1α), Autophagy, chronic obstructive pulmonary disease, aging (Phase 1), Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials2
- Signals6
- Similar companies6